Vivoryon Therapeutics NV Q4 2022 Earnings Call Transcript - Thomson StreetEvents

Vivoryon Therapeutics NV Q4 2022 Earnings Call Transcript

Vivoryon Therapeutics NV Q4 2022 Earnings Call Transcript - Thomson StreetEvents
Vivoryon Therapeutics NV Q4 2022 Earnings Call Transcript
Published Apr 19, 2023
10 pages (5825 words) — Published Apr 19, 2023
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of VVY.AS earnings conference call or presentation 19-Apr-23 1:00pm GMT

  
Brief Excerpt:

...Operator Good day, and thank you for standing by. Welcome to the Full Year 2022 Results Earnings Call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, [Anne Doering]. Please go ahead. Unidentified Company Representative Thank you, Heidi. Good afternoon, and thank you for joining us today for Vivoryon's conference call to discuss the company's full year 2022 results and operational progress. This morning, Vivoryon issued a press release reporting its full year 2022 results, which is posted on the company's website at www.vivoryon.com. On the call with me today are Uli Dauer, Chief Executive Officer of Vivoryon; and Florian Schmid, our Chief Financial Officer. Also with us on today's call and available for questions is Michael Schaeffer, our Chief Business Officer. We will begin today's call with opening remarks from Uli on Vivoryon's clinical and operational progress and then Florian...

  
Report Type:

Transcript

Source:
Thomson StreetEvents
Company:
Vivoryon Therapeutics NV
Ticker
VVY.AS
Time
1:00pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Christian Ehmann - Warburg Research GmbH - Analyst : I have 3 questions, please, and one is towards the VIVIAD trial. You shared with us that you expect the average treatment duration to come out at around 82 weeks. Could you also share the median figure for this treatment duration? Which -- for how long is the median treatment duration? The second question would be, could you give us a little bit -- or can you explain a little bit more into detail the rationale for the VIVA-MIND study expansion to go beyond the initially planned treatment duration in this area? And the third, a little bit similar to my colleague's questions, how is Simcere progressing in China? And how -- or is there a realistic chance that we can see some additional milestone inflows this year besides the EUR 3.8 million you just mentioned? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. APRIL 19, 2023 / 1:00PM, VVY.AS - Q4 2022 Vivoryon Therapeutics NV Earnings Call

Question: Christian Ehmann - Warburg Research GmbH - Analyst : Okay. Could you at least talk about if the median and the average treatment duration is somewhere in the -- somewhere similar in a ballpark area?

Question: Christian Ehmann - Warburg Research GmbH - Analyst : Sure. I understand the problems with this kind of prognosis, but thank you very much for the input.

Table Of Contents

Vivoryon Therapeutics NV at Virtual R&D Event with Key Opinion Leaders Transcript – 2023-10-17 – US$ 54.00 – Edited Transcript of VVY.AS corporate analyst meeting</ 17-Oct-23 11:30am GMT

Half Year 2023 Vivoryon Therapeutics NV Earnings Call Transcript – 2023-09-07 – US$ 54.00 – Edited Transcript of VVY.AS earnings conference call or presentation 7-Sep-23 1:00pm GMT

Vivoryon Therapeutics NV at Barclays Global Healthcare Conference Transcript – 2023-03-16 – US$ 54.00 – Edited Transcript of VVY.AS presentation 16-Mar-23 12:00pm GMT

Vivoryon Therapeutics NV Q3 2022 Earnings Call Transcript – 2022-11-22 – US$ 54.00 – Edited Transcript of VVY.AS earnings conference call or presentation 22-Nov-22 2:00pm GMT

Vivoryon Therapeutics NV Q2 2022 Earnings Call Transcript – 2022-09-30 – US$ 54.00 – Edited Transcript of VVY.AS earnings conference call or presentation 30-Sep-22 1:00pm GMT

Vivoryon Therapeutics NV Corporate Call Transcript – 2022-08-02 – US$ 54.00 – Edited Transcript of VVY.AS conference call or presentation 2-Aug-22 5:15am GMT

Vivoryon Therapeutics NV Annual Shareholders Meeting Transcript – 2022-06-22 – US$ 54.00 – Edited Transcript of VVY.AS shareholder or annual meeting 22-Jun-22 11:00am GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Vivoryon Therapeutics NV Q4 2022 Earnings Call Transcript" Apr 19, 2023. Alacra Store. May 06, 2024. <http://www.alacrastore.com/thomson-streetevents-transcripts/Q4-2022-Vivoryon-Therapeutics-NV-Earnings-Call-T15549034>
  
APA:
Thomson StreetEvents. (2023). Vivoryon Therapeutics NV Q4 2022 Earnings Call Transcript Apr 19, 2023. New York, NY: Alacra Store. Retrieved May 06, 2024 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Q4-2022-Vivoryon-Therapeutics-NV-Earnings-Call-T15549034>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.